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Previewsquestionas towhether binding toHA,OPN,
or something else drives the prosurvival
effects of CD44. Regardless, the efficacy
with which either HA or OPN bind to the
CD44 receptor is probably dependent
on CD44 splice variants. Although the
current study does not find any evidence
for splice variants of CD44 during the
anti-influenza Th1 cell response, further
studies will be needed to clearly elucidate
the function of CD44 for T cells with
regards to the source and availability of
potential binding partners.
It is surprising to note that the role of
CD44 in promoting survival and limiting
Fas-mediated apoptosis applied only to
the Th1 cell subset. Baaten et al. suggest
that this may be due to differences in Fas
expression and reliance on Fas-mediated
apoptosis, given that in their studies,
Th2 cells expressed less Fas after
in vitro polarization. However, Fas-medi-
ated AICD is not confined to Th1 cells
only (Krammer et al., 2007), and at least
one study found that CTL responses to
acute infection are markedly reduced in
the absence of T cell surface expression
of CD44 (Graham et al., 2007). It maybe necessary to study CD44-deficient
responses in the context of in vivo infec-
tion that polarizes different T cell subsets,
rather than with in vitro-polarized T cells.
However, if CD44 does send a survival
signal that is unique to Th1 cells, is there
a separate or broader role for CD44 in
the generation or survival of effector and
memory T cells? Furthermore, because
CD44 signaling impacted Th1-responding
cells regardless of the continued pres-
ence of antigen and the infectious inflam-
matory environment, one intriguing possi-
bility is that CD44 may impact T cell
survival under basal conditions, such as
in the long-term maintenance of Th1
memory cells. From a practical stand-
point, these findings suggest that manip-
ulation of CD44 signaling may provide
a therapeutic lever to promote entry into
AICD and remove unwanted Th1 cell
clones, particularly in settings of trans-
plant rejection or autoimmunity. A better
understanding of CD44 is needed here,
given that in some systems it has been
show to promote apoptosis rather than
survival (Nakano et al., 2007; Ruffell and
Johnson, 2008). We anticipate that theImmunity 3current study by Baaten et al. will provide
an important framework for addressing
these and other questions.REFERENCES
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In this issue of Immunity, Hegazy et al. (2010) report that in response to lymphocytic choriomeningitis virus
(LCMV) infection, fully differentiated virus-specific Th2 cells can be reprogrammed into GATA-3+T-bet+ cells
capable of producing both interleukin-4 and interferon-g.CD4+ T cells, also know as T helper (Th)
cells, play critical roles in orchestrating
adaptive immune responses to a variety
of infectious pathogens, allergens, and
self-antigens. Based on their functions
and their patterns of cytokine expression,
activated Th cells were initially classified
into two lineages, Th1 and Th2 cells (Mos-
mann and Coffman, 1989). Th1 cells
produce interferon-g (IFN-g) and Th2 cells
produce interleukin-4 (IL-4), IL-5, and
IL-13 as their signature cytokines. TheTh1-Th2 cell paradigm dominated the
field for almost two decades, until Th17
(IL-17-producing Th) cells and iTreg
(inducible regulatory T) cells that are also
differentiated from naive CD4+ T cells
were reported (for review, see Zhu and
Paul, 2008). With the discovery of these
unique CD4+ T lineages, the relationship
among these different Th cell types has
become an important question. Many
reports have shown that although the
phenotypes of differentiated Th1 andTh2 cells are relatively stable, Th17 and
Treg cells, including natural-occurring
regulatory T (nTreg) and iTreg cells, are
plastic (for review, see Zhou et al., 2009).
In this issue of Immunity, Hegazy et al.
(2010) show that well-differentiated Th2
cells can also be ‘‘taught’’ by appropriate
stimuli to produce IFN-g both in vivo and
in vitro.
Early studies of Th1 and Th2 cell clones
implied that these cells are terminally
differentiated (Mosmann and Coffman,2, January 29, 2010 ª2010 Elsevier Inc. 11
Figure 1. Reprogramming of Th2 Cells into
GATA-3+T-bet+ Cells
Antigen-specific TCR stimulation and a Th1 cyto-
kine inflammatory environment are required for
inducing T-bet-dependent IFN-g production by
fully differentiated Th2 cells. GP61-68-specific Th2
cells that had been differentiated in vitro for 2–3
weeks express high amounts of GATA-3 and
produce IL-4 upon stimulation. They can respond
to IFN-g and type I interferons (IFN-a and -b), which
induce STAT1 and STAT4 activation. In response
to LCMV infection after transfer, these Th2 cells
are activated by the GP61-68 epitope in the pres-
ence of the inflammatory cytokines, IL-12, IFN-g,
and type I interferons. All these stimuli are required
for inducing GATA-3+T-bet+ ‘‘Th2+1’’ cells capable
of producing both IL-4 and IFN-g. Like Th1 cells,
the ‘‘Th2+1’’ cells upregulate IL-12Rb2 and down-
regulate IFN-gR expression but these cells
continue to express intermediate levels of GATA-3
and IL-4, which is distinct from classic Th1 cells.
The ‘‘Th2+1’’ cells persist and retain their pheno-
type for more than 60 days after LCMV infection.
T-bet-deficient Th2 cells fail to be converted to
‘‘Th2+1’’ phenotype; they are unable to produce
IFN-g but continue to express high amounts of
GATA-3 and IL-4 in response to LCMV infection,
resulting in fatal immunopathology.
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Previews1989). In long-term mouse CD4+ T cell
clones, the expression of IFN-g and IL-4
was mutually exclusive. Both IFN-g and
IL-12, two cytokines that are important
for inducing Th1 cells, also inhibit Th2
cell differentiation (Zhu and Paul, 2008).
Similarly, IL-4, the critical cytokine driving
Th2 cell differentiation, especially in vitro,
suppresses the development of Th1 cells.
The master transcription factors, T-bet
and GATA-3, are also preferentially ex-
pressed in Th1 andTh2 cells, respectively.12 Immunity 32, January 29, 2010 ª2010 ElsIndeed, differentiated Th1 cells fail to
produce IL-4 either when they are reacti-
vated in the presence of IL-4 or when
GATA-3 expression is enforced in these
cells by retroviral-mediated transduction.
It is also difficult to induce IFN-g produc-
tion in fully differentiated Th2 cells with
Th1 cell-inducing cytokines, IL-12 and
IFN-g, although enforced T-bet expres-
sion inTh2cells induces IFN-gproduction.
A recent study using genome-wide
analysis to compare patterns of epige-
netic modifications in a variety of CD4+
cells, including naive, nTreg, differenti-
ated Th1, Th2, Th17, and iTreg cells,
demonstrates that bivalent permissive
and suppressive forms of histone modifi-
cations are found at Tbx21, the gene
locus encoding T-bet, in all non-Th1 cells,
suggesting that these differentiated cells
may retain their capacity to express T-bet
(Wei et al., 2009). This was also true for
histone modifications at the Gata3 locus
in all non-Th2 cells. Although both Th17
and nTreg cells have been shown to
express T-bet and IFN-g when they are
stimulated through their T cell receptor
(TCR) in the presence of IL-12 (Lee et al.,
2009; Wei et al., 2009), our unpublished
data suggest that in contrast to fully differ-
entiated Th17 and Treg cells that can turn
on T-bet expression, fully differentiated
Th2 cells fail to upregulate T-bet and to
acquire IFN-g-producing capacity in
response to IL-12 during reactivation.
Therefore, it seemed curious that bivalent
modifications at the Tbx21 locus were
found in Th2 cells. Hegazy et al. (2010)
now solve this enigma by showing that
differentiated Th2 cells can also be stimu-
lated to express T-bet and to acquire
IFN-g-producing capability when stimu-
lated appropriately. Therefore, the biva-
lent epigenetic modifications at Tbx21
locus found in all non-Th1 cells appear
to underlie the mechanism of plasticity
of these cells to become IFN-g-producing
cells when needed.
Hegazy et al. (2010) show that both
antigen-specific TCR stimulation and an
inflammatory environment that would nor-
mally induce a Th1 cell response are
required for causing Th2 cells to produce
IFN-g in vivo and that such IFN-g produc-
tion completely depends on T-bet upre-
gulation (Figure 1). Seven to ten days after
LCMV infection, transferred Th2 cells,
bearing TCR specific for the LCMV
epitope GP61-68, that have been differenti-evier Inc.ated for 2–3 weeks in vitro, upregulated
T-bet and acquired IFN-g-producing
capacity. However, these Th2 cells failed
to produce IFN-g in mice infected with
a mutant LCMV strain lacking GP61-68,
indicating the importance of TCR stimula-
tion for alteration in cytokine-producing
potential. The cytokines IL-12, IFN-g,
and type I interferons (IFN-a and -b),
which are induced by LCMV infection,
contributed to the conversion of Th2 cells
in vivo. Antigen-specific Th2 cells trans-
ferred into IL-12p40-deficient recipients
produced half as much IFN-g as those
transferred into wild-type mice upon
LCMV infection. IFN-gR1-deficient and
IFN-aR1-deficient Th2 cells almost
completely lost their ability to acquire
IFN-g-producing capacity in response to
LCMV. Therefore, both TCR stimulation
and cytokine-signaling elicited by IL-12,
IFN-g, and type I interferons are required
for upregulating T-bet expression and
inducing IFN-g in differentiated Th2 cells
in vivo.
Hegazy et al. (2010) also show that
cytokine-signaling pathways triggered
by IL-12, IFN-g, and type I interferons
are necessary and sufficient for inducing
IFN-g production by Th2 cells in vitro.
IL-12 and IFN-g, the two cytokines that
are generally used for in vitro Th1 cell
differentiation of naive CD4+ T cells, failed
to convert Th2 cells to IFN-g producers.
This could be accounted for the lack of
IL-12Rb2 expression on Th2 cells and
the resultant failure of IL-12 to activate
STAT4 in these cells, despite the capacity
of Th2 cells to activate STAT1 in response
to IFN-g. Type I interferons activate both
STAT1 and STAT4 in Th2 cells; type I
interferons and IFN-g have an additive
effect on STAT1 activation. It seems likely
that combined stimulation of Th2 cells by
IFN-g and type I interferons results in
expression of IL-12Rb2 on these cells
and their acquisition of responsiveness
to IL-12. Therefore, the combination of
IL-12, IFN-g, and type I interferons is the
key for inducing T-bet expression and
IFN-g production in Th2 cells. The Th2
cells used for the in vivo conversion
experiments had been differentiated for
2–3 weeks in vitro prior to transferring to
the mice that were then infected with
LCMV. By contrast, the Th2 cells used in
the in vitro conversion experiments had
been cultured for only 5 days and thus
may have not been fully differentiated. It
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stimuli besides IL-12, IFN-g, and type I
interferons may be needed for converting
Th2 cells that had been differentiated for
2–3 weeks into T-bet-expressing cells
in vitro.
Hegazy et al. (2010) demonstrate that
when T-bet is upregulated in differenti-
ated Th2 cells both in vivo, by LCMV
infection, and in vitro, by IL-12, IFN-g,
and type I interferons, the expression of
GATA-3 is only modestly suppressed, re-
sulting in GATA-3+T-bet+ ‘‘Th2+1’’ cells. It
has already been shown that some tran-
scription factors of different lineages can
be coexpressed. For example, Foxp3+
RORgt+ cells (Zhou et al., 2008) and
Foxp3+T-bet+ cells (Koch et al., 2009)
have recently been found in vivo. The
discovery of GATA-3+T-bet+ cells raises
the question of the existence of other
transcription factor coexpressers, such
as GATA-3+Bcl-6+ Th2-like follicular
helper T cells and GATA-3+Foxp3+ Th2-
related regulatory T cells.
The GATA-3+T-bet+ cells are able to
produce both IL-4 and IFN-g, an inter-
esting feature also displayed by NKT cells
that have been reported earlier to coex-
press GATA-3 and T-bet. In fact, almost
all the IL-4-producing cells found after
LCMV infection also coexpress IFN-g.
These GATA-3+T-bet+ cells can persist
in animals for more than 60 days after
LCMV infection. However, the physiolog-
ical function of these cells remains to
be carefully tested. For example, it is
unknown that whether these cells will
give protection to LCMV-infected mice
when endogenous Th1 cells are absent.
Hegazy et al. (2010) do show that if these
virus-specific Th2 cells fail to convert into
‘‘Th2+1’’ cells (i.e., if they are derived from
T-bet-deficient donors), they can induce
fatal immunopathology during LCMVinfection. However, this result needs to
be interpreted with care because 1–3
million T-bet-deficient LCMV-specific Th2
cells were transferred in these experi-
ments. Assuming a transfer efficiency of
10%, these mice will have 100,000 or
more highly polarized, recently primed
LCMV-specific Th2 cells, which should
be quite different in both number and
degree of activation than the number of
Th2 memory cells that might exist in
a mouse previously primed under Th2
cell-inducing conditions and then chal-
lenged with a Th1 cell-inducing infectious
agent with a cross-reactive epitope.
Furthermore, will cotransfer of wild-type
and T-bet-deficient virus-specific Th2
cells still induce such fatal immunopa-
thology?
Despite these unresolved issues, this
report is quite important. It dramatically
changes our current view on classic Th1
and Th2 cells and extends the recent
finding of CD4+ T cell plasticity from
Th17 and Treg cells to Th2 cells. It also
provokes many important future ques-
tions. Are in vivo-generated Th2 cells
also plastic? Can one identify ‘‘Th2+1’’
cells in humans? Can these ‘‘Th2+1’’ cells
efficiently exert Th1 or Th2 functions
without having cross-inhibitory effects
between IL-4 and IFN-g? Can Th2 cells
be induced to express IL-17? Because
bivalent histone H3 modifications were
found at the Gata3 locus in non-Th2 cells
similar to the bivalent histone H3 modifi-
cations at the Tbx21 locus in non-Th1
cells, can fully differentiated Th1 cells be
made to express Th2 cytokines?
The plasticity of Th cells in general may
become particularly important when the
naive CD4+ T cell pool is depleted with
age and thus cross-reactivity of memory
cells contributes to the development of
immune responses to newly encounteredImmunity 3pathogens. Under these circumstances,
cross-reactivity and plasticity of the
memory CD4+ T cells may play an impor-
tant role in host defense.
As a general issue, ‘‘plasticity’’ often
means that cells of a given differentiated
type acquire the capacity to produce
a new set of cytokines while retaining
the capacity to produce the cytokines
characteristic of their initial differentiated
state. This could mean that the number
of physiologic Th populationswith distinc-
tive cytokine-producing potential is much
larger than previously thought. If so, this
would appear to pose a complex problem
for the immune system in the sensing of
and differentiation between distinct types
of microbial threats and determining the
appropriate response, both in type and
magnitude.REFERENCES
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